

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number
WO 03/039600 A1

(51) International Patent Classification⁷: **A61K 47/48**,
A61P 35/00, A61K 38/20

(21) International Application Number: PCT/US02/36112

(22) International Filing Date:
8 November 2002 (08.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/332,477 9 November 2001 (09.11.2001) US

(71) Applicant (for all designated States except US):
NEOPHARM, INC. [US/US]; 150 Field Drive, Suite 195,
Lake Forest, IL 60045 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STRAUSS, Lewis**
[US/US]; 1171 Lindenwood Drive, Winnetka, IL 60093
(US). **PURI, Raj** [US/US]; 11412 Ridge Mist Terrace, Po-
tomac, MD 20851 (US).

(74) Agents: **HEFNER, M. Daniel** et al.; Leydig, Voit &
Mayer, Ltd., Two Prudential Plaza, Suite 4900, 180 North
Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SELECTIVE TREATMENT OF IL-13 EXPRESSING TUMORS

(57) Abstract: A method of treating tumors that express a receptor for IL-13 is disclosed. The method involves directly introducing into the tumor a cytotoxin that targets the IL-13 receptor. The cytotoxic agent can be introduced by convection-enhanced delivery through a suitable catheter or by other means. Where a convection-enhanced catheter is employed, the method involves positioning the tip of a catheter at least in close proximity to the tumor. After the catheter is positioned, it is connected to a pump which delivers the active agent through the catheter tip to the tumor. A pressure gradient from the tip of the catheter is maintained during infusion.

WO 03/039600 A1

SELECTIVE TREATMENT OF IL-13 EXPRESSING TUMORS

FIELD OF THE INVENTION

[0001] This invention pertains to a method for selectively treating diseases caused by cells that express IL-13 receptor and particularly to a method of treating solid tumors containing such cells.

BACKGROUND OF THE INVENTION

[0002] Malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) occurs in approximately 17,500 patients annually in the United States. Despite an aggressive multimodal approach to its treatment, no curative therapy is known. Median survival expectation is 9-12 months from diagnosis for GBM and 24-48 months for AA. Despite numerous investigational trials, patients with a recurrence of malignant glioma after initial radiotherapy do not live long.

[0003] One approach to eradicating tumor cells is to target cytotoxic agents to the cells. To accomplish this, antibodies or growth factors that bind to cells can be attached to cytotoxic molecules. The binding sites on such cells are known as cell receptors. This method is selective in situations where the targeted receptors are present in substantially higher amounts on target cells than in normal cells. Selectivity is desirable as it minimizes toxicity to normal cells. Exceptionally high levels of the receptor for Interleukin-13 ("IL13R") have been identified in a number of tumor cells, including malignant gliomas. In contrast, only a few types of normal cells express IL13R and only at low levels. Consequently, IL13 when combined with a cytotoxic agent has the potential to be a highly effective therapeutic agent for the treatment of IL13R-expressing tumor cells.

[0004] To explore the efficacy of such an approach a recombinant fusion protein has been constructed. The fusion protein consists of a truncated bacterial toxin derived from *Pseudomonas*, PE38QQR, fused to IL13. This agent is more completely described and preliminary cytotoxicity studies can be found in *Int. J. Cancer* 92, 168-175, which is incorporated herein by reference in its entirety. Unfortunately, when this therapeutic agent is administered systemically, particularly for malignancies in the central nervous system such as malignant gliomas, the drug does not have suitable efficacy.

[0005] In general poor overall efficacy of systemic chemotherapy for central nervous system malignancies is attributable to the exclusion of most anti-tumor agents from the brain. Moreover, malignant cells evade treatment by invading brain tissue adjacent to a tumor where they are further sheltered from exposure to any drug that does pass through the

blood brain barrier. Thus, even those drugs that do penetrate the blood brain barrier fail to become concentrated in brain tumors and are generally destined to be metabolized and produce undesirable side effects.

[0006] New methods are therefore needed that can be used to deliver tumor-targeting drugs directly to tumors, particularly brain tumors, to produce high drug levels within the tumor while minimizing systemic exposure. Ideally such methods will be useful for treating intra-cranial malignancies, such as glioma, in addition to other solid tumors.

[0007] The invention provides such a method and composition. These and other advantages of the invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

BRIEF SUMMARY OF THE INVENTION

[0008] A method of treating tumors that express a receptor for IL-13 is disclosed. The method involves directly introducing into such tumors a cytotoxin that targets the IL-13 receptor. The cytotoxic agent can be introduced by convection-enhanced delivery through a suitable catheter or by other means. Where a convection-enhanced catheter is employed, the method involves positioning the tip of a catheter at least in close proximity to the tumor. After the catheter is positioned, it is connected to a pump which delivers the active agent through the catheter tip to the tumor. A pressure gradient from the tip of the catheter is maintained during infusion.

DETAILED DESCRIPTION OF THE INVENTION

[0009] The present invention is directed to a method for killing a cell that expresses a receptor for interleukin 13 and that is located in a solid tissue comprising, inserting at least one catheter directly into the solid tissue and through the catheter administering a cytotoxic agent to the solid tissue under pressure at a flow rate of about 30 μ l/h or more to about 1 ml/h for a predetermined period of time such that a portion of the cytotoxic agent contacts a cell that expresses a receptor for interleukin 13 in the solid tissue and kills the cell.

[0010] Any suitable cytotoxic agent that selectively targets tumors that contain cells on which IL-13 receptors reside can be used in practicing the present invention. Such agents typically will have at least two domains, a targeting domain and a cytotoxic domain.

[0011] Suitable targeting domains selectively bind the IL-13 receptor and will generally have an affinity constant for the IL-13 receptor that is at least 1/10,000 of the affinity of native IL-13. In addition, targeting domains must maintain their affinity for the IL-13 receptor when joined to the cytotoxic domain. Suitable targeting domains will include for

example, IL-13 itself and its derivatives. Suitable IL-13 derivatives include genetically constructed derivatives and chemical derivatives. Genetic derivatives can include truncations, deletions, or mutations so long as a suitable binding affinity for IL-13 receptor is maintained. Similarly, chemical modifications of IL-13 include any chemical modifications that do not preclude binding of the targeting moiety to the IL-13 receptor in the cytotoxin.

[0012] Many toxin molecules are known and are suitable for use in the cytotoxic domain. Suitable toxins include pseudomonas exotoxin, ricin, diphtheria toxin, and the like. Suitable cytotoxic domains maintain their cytotoxicity when joined with the targeting domain in the cytotoxin. As with the targeting domain, derivatives of the cytotoxin, including genetic and chemical derivatives are also suitable for use so long as sufficient cytotoxicity is preserved in the ultimate cytotoxin molecule.

[0013] The targeting and cytotoxin domains can be joined by any suitable means that provides for retention of the targeting and cytotoxicity characteristics of the cytotoxin. For example, the two domains can be joined chemically such as through cysteine disulfide or other chemical conjugation methods. Desirably, the domains are joined at the genetic level in a recombinant fusion protein, as is the case with IL13-PE38QQR.

[0014] For administration the drug can be dissolved in any suitable pharmaceutical excipient. Suitable excipients include standard solutions of phosphate-buffered saline, normal saline (0.9 wt.%) and preferably 0.2 wt. % human serum albumin in 0.9 wt.% saline.

[0015] Any disease caused by cells that express the well known IL-13 receptor can be treated by administration of IL13-PE38QQR. For example, malignant glioblastoma multiforme cells, astrocytoma cells, Kaposi sarcoma cells and renal cell carcinoma among other cells express the IL-13 receptor and can be treated. The method can be used to treat a variety of types of tumors, and is especially useful for treating brain tumors, brain stem tumors, and spinal cord tumors.

[0016] Any suitable method for delivering the cytotoxin to the tumor can be used. For example, tumors can be injected with the cytotoxin as through a syringe. Preferably however, the cytotoxin is administered through a catheter by inserting the catheter directly into tissue in the proximity of the tumor. Preferred catheters include those manufactured by Medtronic (e.g., Ventricular #41207, Ventricular #41101, Cardiac/peritoneal #43209, Peritoneal #22014, Peritoneal #22013, #10532, etc.), Phoenix Biomedical Corp (e.g., spiral-port ventricular catheter), and IGN. Other types of catheters (e.g., end-port catheters, side-port catheters, fish-mouth catheters, and the like) also can be employed.

[0017] In use, a catheter is joined with a pump that withdraws the cytotoxin from a container and produces enough pressure to cause the drug to flow through the catheter to the tumor cells at controlled rates. Any suitable flow rate can be used such that the tissue is not disrupted or, in the case of brain tissue, the intracranial pressure is maintained at suitable levels so as not to injure the brain tissue. For example flow rates of about 30 $\mu\text{L}/\text{h}$ or more to about 1 ml/h are easily tolerated in brain tissue. Catheters for convection-enhanced drug delivery and general methods for administering drugs with such devices are known. See, e.g., US Patent 5,720,720; *Am. J. Physiol.* 277, R1218-1229; *Proc. Nat'l Acad. Sci.* (1994) 91, 2076-2080; *J. Neurosurg.* (1995) 82, 1021-1029. More than a single catheter can be used for the infusion if faster rates than can be achieved with a single catheter are desired. In addition, the treatments can be repeated by reinserting the catheters, if they have been removed, and producing a flow of the cytotoxin to the tumor or tissue around the tumor.

[0018] Penetration of the cytotoxin into the tissue is greatly facilitated by positive pressure infusion over a period of days, taking advantage of convection rather than diffusion to aid in drug delivery. This provides for a greater distribution of drug in the treatment area which increases the likelihood that a portion of the drug will come into contact with cells containing IL-13 receptors. When such a contact occurs, the IL-13 targeting domain is thought to bind to the IL-13 receptor. Subsequent to this binding event the cytotoxin enters the cell and the toxin domain poisons the cell thereby causing cell death and obliteration of the disease caused by the cell.

[0019] Any suitable amount of drug that can be administered in this manner. Suitable amounts are amounts that are effective at retarding the growth of or eradicating the disease causing cells without causing an overabundance of undesirable side effects. For example, with IL13-PE38QQR as little as about 1 μg or more to about 1 mg can be administered in a single treatment. More preferably about 2 μg or more to about 600 μg , even more preferably about 4 μg or more to about 400 μg , and still more preferably about 5 μg or more to about 50 μg is administered.

[0020] Tumors can be resected prior to treatment with the drug or, alternatively, tumors can be treated with the drug and then resected. In some case the later procedure may result in the accumulation of necrotic tissue which can be removed. In either situation it is desirable to follow resection with a treatment with the drug so that any disease-causing cells that may have evaded resection and/or the initial drug treatment can be neutralized.

[0021] Recent preclinical data demonstrated that the molecular mechanisms of tumor cytotoxicity induced by IL-13PE38QQR includes the induction of apoptosis in tumor cells (Kawakami et al., *Mol. Cancer Ther.*, 1, 999-1007 (2002)). The data that support this

observation includes: (a) the time dependent induction of proapoptotic caspases 3, 8 and 9 in tumors treated with IL-13PE38QQR; (b) cleavage of procaspase-3 and poly(ADP-ribose) polymerase (PARP) and; (c) the release of cytochrome C from the mitochondria to the cytosol following injection of IL-13PE38QQR intratumorally. These data demonstrate the mechanisms for the anti-tumor activities of IL-13PE38QQR include the induction of tumor cell apoptosis. The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

EXAMPLE 1

[0022] This example demonstrates an effective treatment for malignant glioblastoma multiforme. The method takes advantage of a therapeutic agent that targets receptors for interleukin-13 (IL-13R), an immunoregulatory Th2-derived cytokine, on glioblastoma multiforme cells. Interleukin-13 receptors are over-expressed on human glioblastoma cell lines and primary cell cultures. The cytotoxin comprises a fusion protein composed of human IL-13 and a mutated and truncated form of *Pseudomonas* exotoxin known as PE38QQR. Intratumoral injections of the IL-13 cytotoxin in concentrations of 50 and 100 $\mu\text{g/kg/day}$ for five consecutive days into nude mice having subcutaneous U251 glioblastoma tumors caused a complete response (eradication of the tumor) in 80% and 100% mice, respectively. This response lasted for over eight months after the IL-13 cytotoxin therapy. Three alternate day intratumoral injections of the IL-13 cytotoxin at a dose of 250 $\mu\text{g/kg/day}$ into subcutaneous U87 glioblastoma tumors also produced the same response in all mice.

[0023] Intraperitoneal injections of the IL-13 cytotoxin at 25 or 50 $\mu\text{g/kg/dose}$ for five days, twice daily, caused a regression in U251 tumors of about 45% and 58% and caused a complete response in 1 of 5 and 2 of 5 of the treated animals, respectively. A 50 $\mu\text{g/kg}$ intraperitoneal injection into nude mice having U87 xenografts caused a reduction in the tumor burden to one-half. In addition, daily intravenous injections of IL-13 cytotoxin at doses of 25 and 50 $\mu\text{g/kg}$ for five days suppressed the growth of subcutaneous U251 tumors by 75% and 81% and provided a complete response in 1 of 6 animals in each group. The IL-13 cytotoxin therapy manifested no toxicity in any of the treated mice.

[0024] IL-13 cytotoxin was also directly injected into glioblastoma multiforme tumors xenografted into the right caudate nucleus of nude rat brain. A single injection of 33.3 $\mu\text{g/kg}$ of IL-13 cytotoxin into intracranial tumors increased median survival by >20% compared to control rats.

EXAMPLE 2

[0025] This example demonstrates the maximum tolerated dose of recombinant ligand-targeted cytotoxin IL13-pseudomonas exotoxin 38QQR (IL13-PE38QQR) that can be delivered by a continuous 96 hour intratumoral infusion in patients with recurrent malignant gliomas. The treatment takes advantage of the high density of IL-13 specific receptors on high-grade glioma specimens. Tissue penetration in the brain of this macromolecule is facilitated by positive pressure infusion, taking advantage of convection. A total of 30 patients in groups of 3-6 were selected based on histologic confirmation of malignant glioma and radiographic evidence of recurrence measuring 1.0 to 5.0 cm in maximum diameter, KPS>60. A stereotaxic biopsy at study entry confirmed the presence of glioma. The IL13-PE38QQR was delivered via 2 intratumoral catheters at a rate of 0.2 ml/hr. The concentration of the IL13-PE38QQR in the infusate was increased in each group. Each patient received 2 treatments 8 weeks apart. Three patients have successfully completed both treatment courses at the starting concentration level of 0.125 µg/ml providing for a dose of 4.8 mg.

EXAMPLE 3

[0026] This example demonstrates positive-pressure microinfusion, also known as convection-enhanced delivery, of IL13-PE38QQR to control malignant glioma. Malignant glioma cells, but not normal brain cells, express IL-13 receptors and are thought to internalize IL13-PE38QQR toxin, leading to tumor cell death.

[0027] This example further demonstrates the histologically-effective concentration (HEC). Tumor biopsy and placement of at least one intratumoral catheter is performed on Day 1, and IL13-PE38QQR infusion is performed over 48 hrs at 400 µL/hr on Day 2-4. The tumor is resected on Day 8, with the goal to accomplish an "en-bloc" resection of the tumor with catheter in place. Tumor tissue is evaluated for evidence of a cytotoxic effect including changes in apoptotic index and proliferation rate, as well as necrosis adjacent to the catheter. Following the resection, two or three catheters are placed into brain adjacent to the tumor resection cavity. Post-resection infusion of 750 µL/hr total for 96 hrs is administered on Days 10-14 to treat any residual surviving glioma that has invaded adjacent brain tissue. Pre- and post-resection infusion starts with IL 13-PE38QQR concentrations of 0.25 µg/mL IL13-PE38QQR.

[0028] Pre-operative infusions were well-tolerated in five of six patients tested. In one patient, progressive tumor-related hemiparesis at study entry halted pre-operative drug infusion. In 2 patients, transient changes in affect and cognition were noted during the infusion. All resections and post-resection infusions were well tolerated. One of six

patients receiving post-operative infusions at 0.25 µg/mL experienced steroid-responsive hemiparesis with MRI changes one month later. Tumor specimen in one patient after pre-operative IL13-PE38QQR infusion at 0.5 µg/mL reveals regional necrosis in an ovoid zone extending 2 – 2.5 cm from catheter tip, consistent with drug effect.

[0029] Dose limiting toxicity is defined as any Grade 3 or Grade 4 toxicity which is definitely or probably related to study drug. The maximum tolerated dose (“MTD”) is the dose-level below that which causes dose-limiting toxicity in two or more of up to six patients. Geographic necrosis is defined by loss of cellular integrity with eosinophilic staining or by complete cell loss. The finding of greater than about 90% of cells necrotic in the post-infusion specimen, as compared with the pre-infusion biopsy, in a radial distribution at least 2 cm from the catheter tip, demonstrates drug efficacy.

[0030] Patients are treated with the following concentrations of the drug: 0.2, 0.5, 1, 2, 3, 4, 6, and 8 by infusing the drug in a pharmaceutically acceptable excipient at a rate of 0.4 ml/h for 48 hours when treated prior to tumor resection. This provides doses of 5, 10, 20, 40, 60, 80, 120, and 150 µg. Post resection treatments with the drug is with identical concentrations administered more aggressively at 0.75 ml/min for 96 hours for total doses of 20, 40, 70, 140, 220, 290, 430, and 580 µg, respectively.

[0031] The following Table I demonstrates demographics of six patients:

Table I

	<u>Date of Original Diagnosis</u>	<u>Age</u>	<u>Sex</u>	<u>KPS</u>	<u>Tumor Site; Pathology</u>
Cohort 1					
Patient 1	12/18/00	58	M	100	R temporo-parietal; GBM
Patient 2	2/5/97 (AA)	35	M	100	R temporal; GBM
Patient 3	9/28/98	33	F	100	R parieto-occipital; GBM
Cohort 2					
Patient 4	12/1/99	53	F	80	L fronto-temporo-parietal ; GBM
Patient 5	1/21/97	39	F		L fronto-central ; GBM
Patient 6	1/7/00	45	F	90	R fronto-temporal ; GBM

[0032] The following Table II demonstrates the toxicity profile and efficacy of the drug treatment when administered prior to tumor resection:

Table II

	Pre-Resection IL13-PE38QQR Concentration ($\mu\text{g/mL}$)	Toxicities of Pre-Resection Infusion	Pathology at Resection
Cohort 1			
Patient 1	0.25	Mildly decreased cognition during infusion	No definite necrosis
Patient 2	0.25	Flattened affect & decreased cognition during infusion	No definite necrosis
Patient 3	0.25	Transient field cut	No definite necrosis
Cohort 2			
Patient 4	0.5	None	2 x 2.5 oval region of necrosis around catheter
Patient 5	0.5	Increased R hemiparesis; infusion halted	Fragmentary; insufficient dose
Patient 6	0.5	None	Necrosis, but resection suboptimal for anatomy

[0033] Table II shows that 0.25 $\mu\text{g/mL}$ of the drug is infused intratumorally prior to tumor resection, the treatment was well tolerated. When 0.5 $\mu\text{g/mL}$ of the drug was administered the treatment was well tolerated and demonstrated efficacy as shown by tumor necrosis.

[0034] The following Table III demonstrates the toxicity profile and efficacy of the drug treatment when administered after tumor resection:

Table III

	IL13-PE38QQR Concentration ($\mu\text{g/mL}$)	Toxicities of Post-Resection <u>Infusion</u>	<u>Surgical Issues</u>
Cohort 1			
Patient 1	0.25	None	Post-op field cut
Patient 2	0.25	None	
Patient 3	0.25	None	Only one catheter usable post-op, run at 400 $\mu\text{L/hr}$
Cohort 2			
Patient 4	0.25	Transient severe Rt hemiparesis with abnormal MRI at week 5	Catheter blockage delayed post-op infusion by 1 day
Patient 5	0.25	None	
Patient 6	0.25	None	

[0035] Table III shows that 0.25 $\mu\text{m/ml}$ of the drug is infused into the situs of the tumor after tumor resection, the treatment was well tolerated. When 0.5 $\mu\text{g/ml}$ of the drug was administered the treatment was well tolerated and demonstrated efficacy as shown by tumor necrosis.

[0036] Table IV shows that when 0.25 $\mu\text{m/ml}$ of the drug is infused into the situs of the tumor after tumor resection, the treatment was well tolerated. When 0.5 $\mu\text{g/ml}$ of the drug was administered the treatment was well tolerated and demonstrated efficacy as shown by tumor necrosis.

Table IV

	<u>Study Entry Date</u>	<u>Progression-Free Duration (wks)</u>	<u>Overall Survival Duration (wks)</u>
Cohort 1	6/5/01	22+	22+
Patient 1	6/13/01	9	21+
Patient 2	6/20/01	pend	20+
Patient 3			
Cohort 2	8/9/01	10	13+
Patient 4	8/20/01	pend	12+
Patient 5	8/20/01	11+	11+
Patient 6			

[0037] This example has demonstrated that direct intratumoral infusion of IL13-PE38QQR is well tolerated. Direct intratumoral infusion followed by resection is an efficacious treatment for IL-13-expressing brain tumors. IL13-PE38QQR at concentrations of 0.5 $\mu\text{g/mL}$ is cytotoxic for malignant glioma. In addition, post-operative infusion of IL13-PE38QQR into the brain adjacent to resected tumors is well-tolerated such that malignant glioma can be efficaciously treated by direct infusion with IL13-PE38QQR after resection.

EXAMPLE 4

[0038] In preclinical studies, intracerebral injection of IL13-PE38QQR into rat brain was without neurotoxicity at concentrations up to 100 $\mu\text{g/mL}$. In this trial, the starting concentration is 0.5 $\mu\text{g/mL}$. Since many glioma cell lines are inhibited at concentrations of 1-10 ng/mL , this regimen could provide a therapeutic dose to tumor.

EXAMPLE 5

[0039] In one clinical glioma study intracerebral injection of IL13-PE38QQR is accomplished using a daily volume of 4.8 mL/catheter (0.2 mL/hr x 24 hours), and total infused volume of 38.4 mL/course was held constant. There was a 96 hour infusion at weeks 1 and 9, with the dosing over this period according to the following table:

Table V

Dose level	Dose ($\mu\text{g/mL}$)	Total Dose (μg)
1	0.125	4.8
2	0.25	9.6
3	0.5	19.2
4	1.0	38.4
5	2.0	76.8
6	4.0	153.6
7	6.0	230.4
8	9.0	345.6
9	12.0	460.8

[0040] This study currently is at dose level 4, and data generated to date are presented on the following four pages:

Cohort #1: 0.125 µg/mL for 96 hours, Week 1 and 9

Patient #: Initials; Age; Sex; Dx	Date of Study Entry	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 1-8	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 9-17	Radiographic and/or Pathology Response	Date of Progression	Comments
#1001; CT 42yoM; High grade glioma	11/27/00	11/28/2000 - 12/2/2000; 0.125 µg/mL	---	1/23/2001 - 1/27/2001; 0.125 µg/mL	---	---	3/15/01 PFS: 15 weeks	Last Follow-Up: 9/27/02 Survival: 95+ weeks
#1002; RS 33yoM; Malignant glioma	2/19/01	2/20/2001 - 2/24/2001; 0.125 µg/mL	Abnormal vision; Brain edema (SAE, Week 1, 2/26/01); Headache; Nausea; Vomiting	4/17/2001 - 4/21/2001; 0.125 µg/mL	Brain edema (SAE, Week 14, 5/25/01); Stupor (SAE, Week 14, 5/25/01)	---	5/28/01 PFS: 14 weeks	Date of Death: 11/20/01 Survival: 39 weeks
#1003; JC 55yoM; Malignant glioma	3/5/01	3/6/2001 - 3/10/2001; 0.125 µg/mL	Aphasia; Cranial nerve neuropathy; Motor neuropathy	5/1/2001 - 5/5/2001; 0.125 µg/mL	Aphasia (SAE, Week 11, 5/21/01); Confusion (SAE, Week 11, 5/21/01); Hemiparesis (SAE, Week 11, 5/21/01);	---	6/28/01 PFS: 16 weeks	Date of Death: 7/10/01 Survival: 18 weeks
#2004; JG 51yoM; Recurrent glioblastoma	5/25/01	5/26/2001 - 5/30/2001; 0.125 µg/mL	Hemiparesis (SAE, Week 7, 7/10/01)	NA/CR	Heart arrest (SAE, Week 13, 8/23/01);	Pathologic CR at Week 7	---	Date of Death: 8/23/01 Survival: 13 weeks
#5005; TW 41yoM Malignant astrocytoma	7/10/01	7/13/2001 - 7/17/2001; 0.125 µg/mL	---	NA/PR	---	Radiographic PR at Week 9	3/18/02 PFS: 35 weeks	Last Follow-Up: 9/27/02 Survival: 63+ weeks
#5006; TD 52yoM Recurrent glioblastoma	10/23/01	10/25/2001 - 10/29/2001; 0.125 µg/mL	---	NA/PD	---	---	1/7/02 PFS: 10 weeks	Date of Death: 7/24/02 Survival: 39 weeks

Cohort #2: 0.25 µg/mL for 96 hours, Week 1 and 9

Patient #; Initials; Age; Sex; Dx	Date of Study Entry	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 1-8	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 9-17	Radiographic and/or Pathology Response	Date of Progression	Comments
#1007; JK 51yof; Anaplastic Astrocytoma	12/18/01	12/19/2001- 12/23/2001 0.25 µg/mL	Embolus Lower Extremity (SAE, Week 7, 2/2/02)	NA/PD	---	---	2/8/02 PFS: 7 weeks	Resected on 2/8/02; Date of Death: 2/27/02 Survival: 10 weeks
#2008; MA 52yof; Malignant Glioma	1/9/02	1/10/2002- 1/14/2002 0.25 µg/mL	Pneumocephaly (SAE, Week 2, 1/17/02)	Withdrew Consent	Back Pain (SAE, Week 9, 3/12/02); Motor Neuropathy (SAE, Week 9, 3/12/02)	---	---	Prior SRT Last Follow-Up: 9/27/02 Survival: 37+ weeks
#1009; AS; 46yof; Recurrent Glioma	1/28/02	1/29/2002 - 2/2/2002; 0.25 µg/mL	Aphasia; Thrombosis (SAE, Week 7, 3/15/02)	NA/PD	---	---	3/26/02 PFS: 8 weeks	Last Follow-Up: 9/27/02 Survival: 34+ weeks

Cohort #3: 0.5 µg/mL for 96 hours, Week 1 and 9

Patient #; Initials; Age; Sex; Dx	Date of Study Entry	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 1-8	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 9-17	Radiographic and/or Pathology Response	Date of Progression	Comments
#2010 : DT; 46yoM; Recurrent Astrocytoma	3/22/02	3/23/2002- 3/27/2002 0.5 µg/mL	Deep Thrombophlebitis (SAE, Week 7, 5/9/02)	NA/SAE	Infection (SAE, Week 9, 5/21/02); Deep Vein Thrombosis (SAE, Week 9, 5/21/02)	---	---	Last Follow-Up: 9/27/02 Survival: 27+ weeks
#2011 : RT; 57yoM; Recurrent Residual Malignant Glioma	3/27/02	3/28/2002- 4/1/2002 0.5 µg/mL	---	NA	Ataxia (SAE, Week 12, 6/18/02); Cerebral Edema (SAE, Week 12, 6/18/02); Confusion; Hemiparesis (SAE, Week 12, 6/18/02); Stupor (SAE, Week 12, 6/18/02)	---	---	Last Follow-Up: 9/27/02 Survival: 27+ weeks
#5012 : TH; 43yoM; Recurrent Malignant Glioma	4/4/02	4/5/2002- 4/9/2002 0.5 µg/mL	---	6/5/2002- 6/9/2002 0.5 µg/mL	Ataxia; Hydrocephalus (SAE, Week 17, 7/29/02)	---	7/8/02 PFS: 13 weeks	Only 1 Catheter used, Last Follow-Up: 9/27/02 Survival: 25+ weeks

Cohort #4: 1.0 µg/mL for 96 hours, Week 1 and 9

Patient #, Initials; Age; Sex; Dx	Date of Study Entry	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 1-8	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Weeks 9-17	Radiographic and/or Pathology Response	Date of Progression	Comments
#3013 ; AR; 31yOM; GBM	7/15/02	7/16/2002- 7/20/2002 1.0 µg/mL	Hallucinations; Headache; Seizure	9/10/2002- 9/14/2002 1.0 µg/mL	---	---	---	Last Follow-Up: 9/27/02 Survival: 10+ weeks

EXAMPLE 6

[0041] In another clinical glioma study intracerebral injection of IL13-PE38QQR is accomplished using a 48 hour infusion of 400 $\mu\text{L}/\text{hour}$), starting one week prior to tumor resection, and a 96 hour infusion (750 $\mu\text{L}/\text{hour}$) was begun two days after tumor resection. The treatment was run in three stages as follows:

Stage 1				
	Pre-Resection		Post-Resection	
Dosage level	Dose (µg/ml)	Total dose (µg)	Dose (µg/ml)	Total dose (µg)
1	0.25	4.8	0.25	18.0
2	0.5	9.6	0.25	18.0
3	1.0	19.2	0.25	18.0
4	2.0	38.4	0.25	18.0
Stage 2 (Post Resection)				
Dosage level		Dose (µg/ml)	Total dose (µg)	
1		0.5	36.0	
2		1.0	72.0	
3		2.0	144.0	
Stage 3 (Post Resection)				
Dosage level		Dose (µg/ml)	Total dose (µg)	
1		5	90	
2		6	108	
3		7	126	

[0042] This study currently is at dose level 1 of Stage Two, and data generated to date are presented on the following five pages:

Cohort #1: 0.25 µg/mL Pre-Resection; 0.25 µg/mL Post-Resection

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 1	Pathology	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 2	Date of Progression	Comments
#101; DMH 58yof; R-temporal GBM	12/8/00	6/5/01	6/6/2001 - 6/8/2001; 0.25 µg	Headache	No evidence of necrosis	6/14/2001 - 6/18/2001; 0.25 µg	Fatigue	---	Mild hyponatremia; Visual deficit post-op Last Follow-up: 9/27/02 Progression Free Survival: 68+ Weeks
#102; HJM 35yof; R-temporal GBM	2/5/97 [Initial AA]	6/13/01	6/14/2001 - 6/16/2001; 0.25 µg	Confusion	No evidence of necrosis	6/22/2001 - 6/26/2001; 0.25 µg	Brain edema; Headache; Pain	8/15/01 PFS: 9 Weeks	Partial seizures Increased; quadrantanopia; Progressive Disease Died: 3/13/02 Survival: 39 Weeks
#103; CGM 33yof; R-parieto- occipital GBM	9/28/98	6/20/01	6/21/2001 - 6/23/2001; 0.25 µg	---	No evidence of necrosis	6/29/2001 - 7/3/2001; 0.25 µg	---	9/26/01 PFS: 14 Weeks	Hemiparesis; Paresthesia; Post-op: 1 catheter used, was run at 400 µL/hr, 7 PD vs. transient enhancement Last Follow-up: 9/27/02 Survival: 62+ Weeks

Cohort #2: 0.5 µg/mL Pre-Resection; 0.25 µg/mL Post-Resection

Patient #, Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 1	Pathology	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 2	Date of Progression	Comments
#201; JAR; 53yoF; L Fronto- tempor-parietal GBM	11/30/99	8/9/01	8/10/2001 - 8/12/2001; 0.5 µg	---	2 x 2.5 cm oval necrosis	8/18/2001 - 8/23/2001; 0.25 µg	Hemiparesis (SAE, 9/11/01); Seizure (SAE, 9/11/01)	10/16/01 PFS: 9 Weeks	Catheter kinking delayed post-op infusion; Died 1/3/02 Survival: 21 weeks
#202; NWC; 45yoF; R Fronto- temporal GBM	12/1/99	8/20/01	8/21/2001 - 8/23/2001; 0.5 µg	---	Suboptimal specimen w/ necrosis	8/28/2001 - 9/1/2001; 0.25 µg	Depression; Ear disorder; Fatigue; Headache; Sensory neuropathy	10/24/01 PFS: 9 Weeks Based on Clinical Evidence	AR25 headache/sinusitis. Died 12/23/01 Survival: 17 weeks
#104; TMW 38yoF; L Fronto- parietal GBM	1/22/97	8/20/01	8/22/2001 - 8/23/2001; 0.5 µg Insufficient dose, replaced in enrollment	Headache; Hemiparesis (SAE, before first infusion, 8/21/01); Speech disorder	Fragmentary	8/29/2001 - 9/2/2001; 0.25 µg	Amnesia; Ataxia; Headache; Incoordination; Sensory neuropathy;	9/26/01 PFS: 5 Weeks	Post-op 2 catheters used tolerated well. Patient replaced in enrollment b/c did not receive enough pre-infusion drug Died 3/11/02 Survival: 28 Weeks
#105; S-C 51yoF; GBM	10/16/00	10/30/01	10/31/2001 - 11/2/2001; 0.5 µg	Headache	---	11/8/2001 - 11/12/2001; 0.25 µg	Sensory Neuropathy	12/31/01 PFS: 8 Weeks	Tissue Enhancement (PD vs. Drug) Last Follow-up: 9/27/02 Survival: 47+ Weeks
#203; JWS 46yoM; GBM	12/14/99	11/5/01	11/6/2001 - 11/8/2001; 0.5 µg	---	Major (>75%) necrosis 1 cm from tip	11/13/2001 - 11/17/2001; 0.25 µg	---	2/22/02 PFS: 15 Weeks	Tissue Enhancement (PD vs. Drug) Resected 2/25/02. Last Follow-up: 9/27/02 Survival: 46+ Weeks

Cohort #3: 1.0 µg/mL Pre-Resection; 0.25 µg/mL Post-Resection

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 1	Pathology	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 2	Date of Progression	Comments
#301; MJS 69yoF; GBM	3/14/00	2/8/02	2/9/2002 - 2/11/2002; 1.0 µg	---	1.0 cm necrosis	2/16/2002 - 2/20/2002; 0.25 µg	Pulmonary Embolus (SAE, 4/21/02)	7/24/02 PFS: 23 Weeks	Last Follow-up: 9/27/02 Survival: 33+ Weeks
#401; RRL 57yoM; Grade 3 AA	8/21/01	2/27/02	2/27/2002 - 3/17/2002; 1.0 µg	Speech Disorder	---	3/7/2002 - 3/10/2002; 0.25 µg	Facial Paralysis; Dehydration (SAE, 4/25/02)	7/3/02 PFS: 18 Weeks	Last Follow-up: 9/27/02 Survival: 30+ Weeks
#402; RKW 49yoM; Anaplastic Oligodendrogli oma	3/24/96	3/21/02	3/22/2002 - 3/24/2002; 1.0 µg	Aphasia; Headache; CSF Drainage r/t (SAE, 3/30/02); Seizure; Sensory Neuropathy	---	4/1/2002 - 4/4/2002; 0.25 µg	CSF leakage f/u (SAE, 3/30/02); Headache; Pneumocephalus (SAE, 4/10/02); Meningitis (SAE, 4/15/02); Craniotomy Flap Edema (SAE, 4/23/02); Pulmonary Embolus (SAE, 5/11/02)	6/21/02 PFS: 13 Weeks	Last Follow-up: 9/27/02 Survival: 27+ Weeks
#106; HLW 52yoM; Anaplastic Oligoastrocyto ma	4/9/00	3/26/01	3/27/2002 - 3/29/2002; 1.0 µg	---	---	4/4/2002 - 4/8/2002; 0.25 µg	Headache; Motor Neuropathy; Seizure; Sensory Neuropathy; Broken Leg (SAE, 8/21/02)	---	Last Follow-up: 9/27/02 Progression Free Survival: 28+ Weeks

Cohort #4: 2.0 µg/mL Pre-Resection; 0.25 µg/mL Post-Resection

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Infusion #1 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 1	Pathology	Infusion #2 Date; Dose	Related AEs Grade ≥ 2 and SAEs: Infusion 2	Date of Progression	Comments
#107; KJN 24yoF; GBM	1/3/02	5/14/02	5/15/2002 - 5/17/2002; 2.0 µg	---	---	5/23/2002 - 5/27/2002; 0.25 µg	---	---	Last Follow-up: 9/27/02 Progression Free Survival: 19+ Weeks
#302; PCJ 48yoM; GBM	---	5/17/02	5/18/2002 - 5/20/2002; 2.0 µg	Hyponatremia (SAE, Week 1, 5/21/02); Headache (SAE, Week 1, 5/21/02); Vomiting (SAE, Week 1, 5/21/02)	---	5/25/2002 - 5/29/2002; 0.25 µg	CSF Leakage (SAE, Week 6, 6/22/02); Expressive Dysphasia (SAE, Week 11, 7/26/02)	8/22/02 PFS: 14 Weeks	Died: 9/25/02 Survival: 18 Weeks
#303; DMD 43yoM; GBM	10/18/01	6/5/02	6/6/2002 - 6/8/2002; 2.0 µg	---	---	6/13/2002 - 6/17/2002; 0.25 µg	---	8/6/02 PFS: 9 Weeks	Last Follow-up: 9/27/02 Survival: 16+ Weeks

Cohort #5: 0.5 µg/mL Post-Resection

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Resection/ Catheter Date	Post Resection Infusion Date; Dose	Infusion Related AEs Grade ≥ 2 and SAEs	Date of Progression	Comments
#204; CAM 60yom; GBM	4/3/02	7/24/02	7/26/2002 -7/30/2002; 0.5 µg	Pulmonary Embolism (SAE, Week 2, 7/31/02); Deep Vein Thrombosis (SAE, Week 2, 8/2/02)	8/19/02 PFS: 3 Weeks	Last Follow-up: 9/27/02 Survival: 9+ Weeks
#205; LJP 56yom; GBM	1/8/02	7/29/02	7/31/2002 -8/4/2002; 0.5 µg	Thrombosis (SAE, Week 2, 8/8/02); Hemiparesis (SAE, Week 8, 9/17/02)	---	Last Follow-up: 9/27/02 Progression Free Survival: 9+ Weeks
#108; J-V 47yom; GBM	4/3/02	7/29/02	7/31/2002 -8/4/2002; 0.5 µg	---	---	Last Follow-up: 9/27/02 Progression Free Survival: 9+ Weeks

EXAMPLE 7

[0043] In another clinical study intracerebral injection of IL13-PE38QQR is accomplished using escalating infusion duration from 4 days (51.8 mL) to a maximum of 7 days (90.7 mL), to identify a MTD based on infusion duration; infusion rate held constant at 540 mL/hr (total) as follows:

Dose level	Conc. ($\mu\text{g}/\mu\text{L}$)	Duration (Days)	Total Dose (μg)	Increment (%)
1	.05	4	25.9	---
2	.05	5	32.4	25
3	.05	6	38.9	20
4	.05	7	45.4	16.7

[0044] A second protocol is employed in which concentration escalated from 1.0 mg/mL to a maximum of 4.0 mg/mL (assuming 7-day infusion) to identify a MTD based on concentration; infusion rate held constant at 540 mL/hr (total) as follows:

Dose level	Conc. ($\mu\text{g}/\mu\text{L}$)	Total Dose (μg)	Increment (%)
1	1.0	90.7	100
2	2.0	181.4	100
3	3.0	272.2	50
4	4.0	362.8	33

[0045] This study currently is at dose level 2, and data generated to date are presented on the following two pages:

Cohort #1: 0.5 µg/mL x 4 Days

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Pre-resection Infusion Date	Date of Resection	Related AEs Grade ≥ 2 and SAEs	Pathology	Date of Progression	Comments
0110-1101; JK; 48 yof; Anaplastic Glioma	4/28/92	7/30/02	7/31/02	8/13/02	Seizure (Grade 2); Headache (Grade 2)	---	---	---
0108-1102; B-C; 56 yom; Glioblastoma	8/8/01	8/5/02	8/6/02	8/19/02	---	---	---	---
0108-1103; Y-E; 54 yom; Glioblastoma Multipiforme	7/9/01	8/12/02	8/13/02	8/26/02	---	---	---	---

Cohort #2: 0.5 µg/mL x 5 Days

Patient #; Initials; Age; Sex; Dx	Date of Diagnosis	Biopsy/ Catheter Date	Pre-resection Infusion Date	Date of Resection	Related AEs Grade ≥ 2 and SAEs	Pathology	Date of Progression	Comments
0108-1201; I-P; 35 yo F; GBM	4/1999	9/30/2002	10/1/2002	10/14/2002 Projected	---	---	---	---
0108-1202; Z-F; 61 yo M; GBM	3/2002	9/30/2002	10/1/2002	10/14/2002 Projected	---	---	---	---

[0046] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0047] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0048] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations of those preferred embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

WHAT IS CLAIMED IS:

1. A method for killing a cell that expresses a receptor for interleukin 13 and that is located in a solid tissue comprising, inserting at least one catheter directly into said solid tissue and administering a cytotoxic agent to said solid tissue under pressure through said catheter into the solid tissue at a flow rate of about 30 μ l/h or more to about 1 ml/h for a predetermined period of time such that a portion of said cytotoxic agent contacts a cell that expresses a receptor for interleukin 13 in said solid tissue and kills said cell.
2. A method for treating a solid tumor that contains cells that express a receptor for IL-13 comprising inserting at least one catheter directly into said solid tumor and administering a cytotoxic agent to said solid tumor under pressure through said catheter into the solid tumor at a flow rate of from about 30 μ l/h to about 1 ml/h for a predetermined period of time such that a portion of said cytotoxic agent contacts a cell that expresses a receptor for interleukin 13 in said solid tumor and kills said cell.
3. A method for treating a solid tissue tumor that contains cells that express a receptor for IL-13 comprising inserting at least one catheter directly into solid tissue in proximity to a tumor that contains cells that express a receptor for IL-13 and administering a cytotoxic agent under pressure through said catheter toward said tumor at a flow rate of from about 30 μ l/h to about 1 ml/h for a predetermined period of time such that a portion of said cytotoxic agent contacts a cell that expresses a receptor for interleukin 13 in said solid tumor and kills said cell.
4. The method of any of claims 1-3, wherein the cytotoxic agent comprises a portion of IL-13 that binds to an IL-13 receptor.
5. The method of any of claims 1-4, wherein the cytotoxic agent comprises a portion of IL-13 that binds to an IL-13 receptor fused to a toxin.
6. The method of any of claims 1-5, wherein the cytotoxic agent is IL13-PE38QQR.
7. The method of any of claims 1-6, wherein said step of inserting at least one catheter directly into said solid tissue and administering a cytotoxic agent to said solid tissue is repeated.

8. A method for killing a cell that expresses a receptor for interleukin 13 and that is located in a solid tissue comprising, inserting at least one catheter directly into said solid tissue and administering about 1 μ g or more to about 1 mg IL13-PE38QQR to said solid tissue under pressure through said catheter into the solid tissue in a predetermined period of time such that a portion of said IL13-PE38QQR contacts a cell that expresses a receptor for interleukin 13 in said solid tissue and kills said cell.

9. The method of claim 8, wherein about 2 μ g or more to about 600 μ g IL13-PE38QQR is administered to said solid tissue.

10. The method of claim 8, wherein about 4 μ g or more to about 400 μ g IL13-PE38QQR is administered to said solid tissue.

11. The method of claim 8, wherein about 4 μ g or more to about 100 μ g IL13-PE38QQR is administered to said solid tissue.

12. The method of claim 8, wherein about 5 μ g or more to about 50 μ g IL13-PE38QQR is administered to said solid tissue.

13. The method of any of claims 8-12, wherein said step of inserting at least one catheter directly into said solid tissue and administering a cytotoxic agent to said solid tissue is repeated.

14. The method of any of claims 1-13, further comprising resecting said tissue or said tumor.

15. The method of any of claims 1-14, where said cell is within a tumor.

16. The method of claim 15, wherein said tumor is a glioma.

17. The method of claim 15 or 16, wherein said tumor is a brain cancer tumor, or a brain stem cancer tumor.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/36112

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 A61P35/00 A61K38/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08957 A (PENN STATE RES FOUND) 5 March 1998 (1998-03-05) abstract page 47, line 6 - line 24 ---	1-17
X	WO 99 51643 A (PENN STATE RES FOUND) 14 October 1999 (1999-10-14) abstract page 29, line 28 -page 30, line 11 page 34, line 4 - line 13 ---	1-17
X	WO 00 40264 A (DEBINSKI WALDEMAR ;CONNOR JAMES R (US); PENN STATE RES FOUND (US)) 13 July 2000 (2000-07-13) abstract page 7, line 18 -page 8, line 21 --- -/-	1-17

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

13 February 2003

Date of mailing of the international search report

10/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 02/36112

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 25282 A (DEBINSKI WALDEMAR ; PENN STATE RES FOUND (US); THOMPSON JEFFREY P (US)) 12 April 2001 (2001-04-12) abstract page 34, line 18 -page 35, line 16	1-17
X	KAWAKAMI KOJI ET AL: "Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer." CANCER RESEARCH, vol. 61, no. 16, 15 August 2001 (2001-08-15), pages 6194-6200, XP002230995 ISSN: 0008-5472 abstract page 6196, column 2, line 26, paragraph 4 - paragraph 5 page 6198, column 2, paragraph 1 - paragraph 2	1-17
X	HUSAIN S R ET AL: "Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft." BLOOD. UNITED STATES 1 JUN 2000, vol. 95, no. 11, 1 June 2000 (2000-06-01), pages 3506-3513, XP002230996 ISSN: 0006-4971 abstract page 3509, column 2, paragraph 5 -page 3510, column 2, paragraph 4 "Discussion"	1-17
X	HUSAIN SYED R ET AL: "Interleukin-13 receptor as a unique target for anti-glioblastoma therapy." INTERNATIONAL JOURNAL OF CANCER, vol. 92, no. 2, 2001, pages 168-175, XP002230997 ISSN: 0020-7136 cited in the application abstract page 171, column 2, line 2 -page 172, column 1, line 2 "Discussion"	1-17
X	DATABASE DRUGNL 'Online! STN; Database accession no. 2000:1410 XP002230998 abstract & "IL-13-PE38QQR Food and Drug Administration preclinical data" R&D FOCUS DRUG NEWS, 1 May 2000 (2000-05-01),	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

II International Application No

PCT/US 02/36112

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9808957	A	05-03-1998	US 6428788 B1	06-08-2002
			AU 4164097 A	19-03-1998
			WO 9808957 A1	05-03-1998
			US 2002031492 A1	14-03-2002
WO 9951643	A	14-10-1999	US 6296843 B1	02-10-2001
			AU 752086 B2	05-09-2002
			AU 3377499 A	25-10-1999
			CA 2325341 A1	14-10-1999
			EP 1071717 A1	31-01-2001
			JP 2002510711 T	09-04-2002
			US 2002159972 A1	31-10-2002
			WO 9951643 A1	14-10-1999
			US 2002119120 A1	29-08-2002
WO 0040264	A	13-07-2000	US 2001053371 A1	20-12-2001
			AU 2223800 A	24-07-2000
			CA 2358427 A1	13-07-2000
			EP 1140167 A1	10-10-2001
			JP 2002534395 T	15-10-2002
			WO 0040264 A1	13-07-2000
			US 2002031492 A1	14-03-2002
WO 0125282	A	12-04-2001	AU 7863900 A	10-05-2001
			EP 1222212 A1	17-07-2002
			WO 0125282 A1	12-04-2001
			US 2002159972 A1	31-10-2002